Feature | May 22, 2006| Ryan Hiett

The Artificial Heart of Texas

How one cardiovascular center is staying true to its mission with the most recent developments in heart pump technology

CardiacAssist Inc.'s TandemHeart PTVA in action.

CardiacAssist Inc.'s TandemHeart PTVA in action.

CardiacAssist Inc.'s TandemHeart PTVA in action.

Give a highly ranked research and teaching facility access to cutting-edge technology, and the results could be death defying.
At least that’s true for the Texas Heart Institute (THI) of St. Luke’s Episcopal Hospital (Houston, TX) and its research with the latest in percutaneous left ventricular assist devices.
Mortality rates have been cut by as much as 80 percent nationwide with the TandemHeart PTVA (CardiacAssist Inc., Pittsburgh, PA), making its predecessor obsolete, according to THI cardiologist and heart failure specialist Reynolds M. Delgado, M.D.
THI is one of the first institutions to implant the device, which received FDA clearance a little over two years ago, and is using it more frequently than any other institute in the world — 45 cases in 2005 alone.
Dr. Delgado calls it a “dramatic lifesaver.”
“We have put the device in patients who are on death’s door, supported them, reversed their organ failure and got their bodies back in shape,” he said.
By connecting an external pump to the circulatory system via input and output cannulas, the device supplements the heart’s pumping action, improving blood flow until the patient is strong enough to undergo surgery or angioplasty.
It has also been successful in supporting circulation during high-risk coronary interventions, according to Dr. Delgado.
“High-risk stenting, for example,” he said. “The TandemHeart allows us to do that on an awake patient, without putting him under anesthesia, and we can support circulation while the left main stent is being done.”

Hospital of 1,000 Heart Implants
THI’s success with the device demonstrates its mission of reducing the toll of cardiovascular disease through programs in research, education and patient care.
“It’s a unique model,” said Dr. Delgado. “As a research and teaching entity, it causes a draw for the best and brightest minds in heart disease care.”
Founded in 1962, THI is one of the first standalone cardiovascular institutes in the nation and has been ranked one of the top 10 institutions by U.S. News and World Report for the past 15 consecutive years.
“It’s the first of its kind in this part of the country,” Dr. Delgado said. “So over the years it has really established a strong history of excellence in cardiovascular care.”
The hospital is known for being a pioneer in both artificial and human heart implants.
“We are one of the first centers to implant artificial hearts,” he said. “They are getting smaller and smaller — we now have a pump device that can be implanted in the heart that is as big as a D cell battery that can pump all the blood supply requirements of the body.”
That device is the Jarvik 2000, a valveless, electrically powered miniature axial flow pump that fits directly into the left ventricle and pushes oxygenated blood throughout the body. It is still in experimental stages.
Denton A. Cooley, M.D., THI president and surgeon-in-chief, performed the first successful heart transplant in the U.S. in 1968 and THI chief of cardiovascular transplantation and director of surgical research Bud Frazier, M.D., and his team completed their 1,000th heart transplant this year.
"The devices we've been developing and testing are either ventricular assist devices or artificial hearts,” Dr. Frazier said. “They are all pumps of some type, but they each work differently for a specific function."

Vision of Education
THI’s Heart Information Center provides educational information related to the prevention, diagnosis and treatment of cardiovascular disease.
“One of our strongest visions is education,” Dr. Delgado said. “We have several educational seminars — we are actually in the process of developing one specifically for the TandemHeart.”
Dr. Delgado says the training programs are aimed toward long-term education.
“It’s a wonderful experience for the doctors in training to be able to learn cutting-edge technology,” he said. “Then, wherever they end up practicing, they can take that knowledge with them.”
The institute also has programs ranging from continuing medical to children’s education.
Project Heart is a Web site focused on teaching the basics of the cardiovascular system and cardiovascular health to elementary school children. The program extends the community outreach mission to educators by offering comprehensive curriculum materials from kindergarten through third grade.

Related Content

TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral| August 02, 2016
August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L.
Biotronik, ORIENT trial results, EuroPCR 2016, Orsiro DES, hybrid drug-eluting stent
News | Stents Drug Eluting| June 03, 2016
Biotronik announced results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to the Resolute...

Biosensors' Biomatrix stent.

Feature | Stents| May 16, 2016
May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables Co
Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting| April 21, 2016
Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its novel, next-...
Absorb, bioresorbable stents
Feature | Stents Bioresorbable| April 13, 2016 | Dave Fornell
Bioresorbable stents have been one of the hottest new cardiovascular technologies discussed at cardiology meetings ov
Biotronik, BIOSCIENCE trial, Orsiro hybrid DES, drug-eluting stent, STEMI heart attack patients
News | Stents Drug Eluting| March 07, 2016
Biotronik announced publication of results from the BIOSCIENCE trial in the journal EuroIntervention. The study’s...
Medtronic, CE Mark, Resolute Onyx DES, drug-eluting stent, expanded sizes and indications
News | Stents Drug Eluting| February 02, 2016
Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES,...
News | Stents Drug Eluting| January 08, 2016
In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient randomized clinical...
Sponsored Content | Videos | TCT| November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Overlay Init